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Ar ticle

STING-associated vasculopathy develops independently
of IRF3 in mice
James D. Warner,1* Ricardo A. Irizarry‑Caro,4* Brock G. Bennion,3 Teresa L. Ai,3 Amber M. Smith,1
Cathrine A. Miner,1 Tomomi Sakai,4 Vijay K. Gonugunta,4 Jianjun Wu,4 Derek J. Platt,2 Nan Yan,4,5
and Jonathan J. Miner1,2,3
Department of Medicine, 2Department of Molecular Microbiology, and 3Department of Pathology and Immunology, Washington University School of Medicine,
St. Louis, MO
4
Department of Immunology and 5Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX

P atients with stimulator of interferon genes (STING)–associated vasculopathy with onset in infancy (SAVI) develop systemic
inflammation characterized by vasculopathy, interstitial lung disease, ulcerative skin lesions, and premature death. Autosomal
dominant mutations in STING are thought to trigger activation of IRF3 and subsequent up-regulation of interferon (IFN)stimulated genes (ISGs) in patients with SAVI. We generated heterozygous STING N153S knock-in mice as a model of SAVI.
These mice spontaneously developed inflammation within the lung, hypercytokinemia, T cell cytopenia, skin ulcerations, and
premature death. Cytometry by time-of-flight (CyTOF) analysis revealed that the STING N153S mutation caused myeloid cell
expansion, T cell cytopenia, and dysregulation of immune cell signaling. Unexpectedly, we observed only mild up-regulation of
ISGs in STING N153S fibroblasts and splenocytes and STING N154S SAVI patient fibroblasts. STING N153S mice lacking IRF3
also developed lung disease, myeloid cell expansion, and T cell cytopenia. Thus, the SAVI-associated STING N153S mutation
triggers IRF3-independent immune cell dysregulation and lung disease in mice.
INTRODUCTION
Stimulator of type I IFN genes (TMEM173; STING) is a
cytosolic nucleic acid sensor that plays a critical role in the
cell-intrinsic innate immune response to microbial DNA and
cyclic dinucleotides, as well as to aberrant host DNA (Stetson, 2012; Gao et al., 2013; Li et al., 2016). Genetic deletion
of STING in mice results in impaired immunity to a variety
of pathogens including bacteria and viruses (Ishikawa et al.,
2009; Schoggins et al., 2014; Parker et al., 2015). In humans,
several autosomal dominant de novo or inherited mutations
in STING have been reported in STING-associated vasculopathy with onset in infancy (SAVI) and patients with familial
chilblain lupus (Jeremiah et al., 2014; Liu et al., 2014; Picard
et al., 2016; König et al., 2017). One of the most frequently
found SAVI mutations is STING N154S (N153S in mouse orthologue), a mutation that is thought to constitutively activate
IRF3 to induce transcription of IFN-β and IFN-stimulated
genes (ISGs; Liu et al., 2014). SAVI patients with the STING
N154S mutation develop systemic inflammatory disease characterized by vasculopathic lesions that affect the lung and skin
(Liu et al., 2014). The resulting clinical syndrome includes interstitial lung disease, ulcerative skin lesions, digital ischemia,
and T cell cytopenia (Liu et al., 2014; Picard et al., 2016).
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STING resides on the ER and is activated by cGAMP,
a cyclic dinucleotide second messenger that is produced by
cGAMP synthase (cGAS) upon detection of cytosolic host or
microbial DNA (Stetson, 2012; Schoggins et al., 2014; West
et al., 2015; Li et al., 2016). Binding of cGAMP to STING
triggers a conformational change in the STING C terminus
(Ouyang et al., 2012) and subsequent ER-to-vesicle trafficking (Dobbs et al., 2015), which activates downstream effectors
including TANK-binding kinase 1 (TBK1; Tanaka and Chen,
2012) and IκB kinase (Ishikawa and Barber, 2008). TBK1
phosphorylates IRF3, which leads to IRF3 translocation into
the nucleus and transcriptional activation of IFN-β and ISGs
(Li et al., 2016; Wang et al., 2016). Activation of the type I
IFN response via IRF3 is thought to be the driving force
behind SAVI disease pathogenesis (Liu et al., 2014), although
this hypothesis was not previously tested experimentally in
an animal model of the disease. Interestingly, one recent study
provided evidence that abnormalities in T cell proliferation
in human patients with SAVI occur independently of any
interaction with TBK1 and IRF3 (Cerboni et al., 2017).
Thus, there is a need for models of SAVI that will allow in
vivo testing of previously hypothesized mechanisms of disease pathogenesis, beyond cell culture studies of IRF3 activation. Here, we describe the generation of STING N153S
knock-in mice as a model of SAVI. Like SAVI patients, the
© 2017 Warner et al. This article is distributed under the terms of an Attribution–Noncommercial–Share
Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org
/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
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Figure 1. Spontaneous disease and mortality in STI
NG N153S mice. (A) Electropherogram of WT and STING N153S mutant
alleles within exon 5. (B) Spleens from WT
littermate control and STI
NG N153S mice.
(C) STING N153S mouse lungs with surrounding pleural effusions, indicated by the yellow
arrows. (D) Representative skin ulcerations
(yellow arrows) on the extremities and head of
STING N153S mice. (E) Mortality was assessed
in STING N153S male and female mice (n = 21)
for 180 d. Three pregnant female mice (#) succumbed to disease. No mortality occurred in
WT littermate control animals (n = 20).

RESULTS
STING N153S mice develop spontaneous lung and skin
disease, causing premature death
The original description of SAVI found that four of six patients had the STING N154S mutation (Liu et al., 2014;
N153S in mouse STING), a mutation that we previously
confirmed to cause up-regulation of type I IFN in 293T
cell assays (Dobbs et al., 2015). Thus, we chose to introduce
the STING N153S mutation in mice to produce a model
of SAVI. Using CRISPR/Cas9, we generated heterozygous
STING N153S mice by introducing a DNA oligonucleotide donor containing a two-nucleotide missense mutation
into exon 5 of TMEM173 (STING), which resulted in replacement of asparagine 153 with serine (STING N153S;
Fig. 1 A). Homozygous knock-in mice did not survive
gestation, whereas adult STING N153S heterozygous animals (STING N153S mice) developed spontaneous disease
characterized by splenomegaly (Fig. 1 B), pleural effusions
(Fig. 1 C), and ulcerative skin lesions of the extremities of
five mice and on the head of one 9-mo-old STING N153S
animal (Fig. 1 D). Severe respiratory distress occurred frequently, required euthanasia, and was sometimes observed
during late pregnancy in STING N153S dams that were
unable to survive labor (Fig. 1 E). Histopathological evaluation of the lung revealed chronic perivascular inflammation with heterogeneous immune cell infiltration (Fig. 2 A,
black arrows) and organized thrombosis in pulmonary
2

blood vessels (Fig. 2 A, red arrows). Higher-magnification
images (Fig. 2 B) and flow cytometric analysis of immune
cells in the lungs of STING N153S mice revealed substantially increased numbers of immune cells (two- to fourfold,
P < 0.05), predominantly consisting of CD19+ B cells and
CD11b+ myeloid cells, with smaller numbers of CD4+ and
CD8+ T cells (Fig. S1). Because SAVI patients frequently
develop interstitial lung disease, we performed a histological assessment for pulmonary fibrosis by Gomori trichrome
staining of STING N153S lungs, but we found no evidence
of pulmonary fibrosis, even in animals that were evaluated at
necropsy after spontaneous death caused by respiratory distress (Fig. 2 C). Histopathological assessment of skin lesions
revealed mixed immune cell infiltration, ulceration, and
scarring (Fig. 2 D). Some features of disease are shared in
SAVI and systemic lupus erythematosus (Balada et al., 2016),
but unlike many patients with systemic lupus, SAVI patients
do not develop glomerulonephritis. Consistent with SAVI
in humans, we found no evidence of inflamed or abnormal glomeruli in STING N153S mice (Fig. 2 E). However,
histopathological examination of the spleen consistently
demonstrated abnormal architecture (Fig. 2 F), suggesting
that the STING N153S mutation may trigger immune cell
dysregulation in secondary lymphoid organs.
Because some SAVI patients develop autoantibodies
(Liu et al., 2014), we quantitated levels of total IgM and IgG
antibodies and performed autoantigen array analysis of serum
from STING N153S mice and WT littermate control animals. Three of five STING N153S mice produced higher
levels of IgM but not IgG autoantibodies compared with WT
littermates (Fig. 3). However, all five of the STING N153S
Mouse model of STING-associated vasculopathy | Warner et al.
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mice developed T cell cytopenia, myeloid cell expansion, and
spontaneous pulmonary inflammation, which occurred independently of IRF3 in mice.
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Figure 2. STING N153S mice develop spontaneous perivascular inflammation of the lung. (A) Hematoxylin and eosin (H&E) images of paraffin-embedded lung sections from 4–5-mo-old STING N153S and WT littermate control mice. Pulmonary blood vessels (v) and bronchioles (b) are
indicated. Top, black arrows indicate perivascular immune cell infiltrate. Bar, 100 µm. Bottom, red arrows indicate organized thrombosis. Bar, 50 µm.
(B) High-magnification H&E images of WT (left) and STING N153S (right) lung sections. Bar, 5 µm. (C) Gomori trichrome staining of WT and STING N153S
lung sections. Bar, 100 µm. (D) H&E staining of WT as well as STING N153S skin from the ulcerated skin lesion on a hind limb. Bar, 50 µm. (E) H&E staining
of representative STING N153S and WT littermate glomeruli. Bar, 10 µm. (F) H&E staining of WT and STING N153S spleens. Bar, 100 µm. Spleen and kidney
histology is representative of n = 3 mice per genotype from three independent experiments. Skin histology is representative of n = 2 mice per genotype.
Lung histology is representative of seven mice per genotype from three independent experiments.

mice had severe lung disease, including animals without detectable autoantibodies, suggesting that autoantibodies are
not required for disease pathogenesis in mice. A multiplexed
cytokine assay performed on the serum of 4–6-mo-old
STING N153S mice and WT littermate controls revealed elJEM

evated levels of multiple cytokines and chemokines including
TNF, IL-17A, IL-13, G-CSF, MIP-1α, MIP-1β, MCP-1, and
IL-10 (2–23-fold increase, P < 0.05; Fig. 4). Thus, STING
N153S mice develop hypercytokinemia and spontaneous inflammation of the lung and skin.
3

Figure 3. Increased IgM autoantibodies in the serum of STING
N153S mice. Immunoglobulin analysis of WT and STING N153S mouse
serum (n = 9). (A and B) Quantitation of total IgG (A) and total IgM (B).
(C) Heat maps of IgG and IgM autoantibodies against autoantigens. n =
4

9 per genotype. ****, P < 0.0001; ns, not significant. Data are the result of
two independent experiments with four to five samples per experiment
and were analyzed by Mann–Whitney test. Error bars represent SEM.
Mouse model of STING-associated vasculopathy | Warner et al.
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The STING N153S mutation causes myeloid cell expansion
and cell-intrinsic T cell cytopenia
SAVI patients were previously reported to have T cell cytopenia and impaired myeloid cell differentiation (Liu et al., 2014).
To begin to characterize immune cells in STING N153S
mice, we used cytometry by time-of-flight (CyTOF) to assess immune cell populations in the spleen (Fig. 5). Although
we detected no difference in numbers of splenic CD45+ and
CD19+ cells in STING N153S mice, there was a deficiency
in T cells (22 × 106 CD3+ cells in WT vs. 2.9 × 106 in STING
N153S; P < 0.005), which was more severe, and consistently
observed, for CD8+ T cells than for CD4+ T cells (Fig. 5,
A–C and F–H). Additionally, we observed marked expansion
of Ly6G+ myeloid cells (0.6 × 106 in WT vs. 9.5 × 106 in
STING N153S; P < 0.005; Fig. 5, A–C and I) and immature myeloid cells (CD11b+cKit+MHCII−; Fig. 5 A). Also,
in T and NK cells, activation markers including CD44 were
up-regulated (Fig. 5, J and K), which may occur as a direct
result of cell-intrinsic STING signaling or may reflect an indirect consequence of chronic hypercytokinemia.
To test whether T cell cytopenia may result from
NG N153S mutation, we
cell-intrinsic effects of the STI
generated mixed bone marrow chimeras by comparing WT
NG
Thy1.1+ versus either WT littermate control or STI
N153S marrow transplanted into CD45.1 recipients (Fig. 6 A).
In the competition between the Thy1.1+ and STING N153S
donors, CD4+ and CD8+ T cells were predominantly generated from WT Thy1.1+ bone marrow, revealing that the
STING N153S T cell deficiency is intrinsic to the hematopoietic compartment (Fig. 6, B and C). To further evaluate
the cause of splenic T cell deficiency, we performed CyTOF
analysis of thymocytes (Fig. 7) and found a decrease in total
numbers of thymocytes (2.7-fold in STING N153S compared with WT, P < 0.005), a large increase in the number and
percent of thymic B cells (0.13% in WT vs. 2.5% in STING
N153S, P < 0.005), and a lower fraction of double-negative
T cells (1.8% in WT vs. 1.2% in STING N153S, P < 0.005;
Fig. 7). Although diminished in total number, the percentages
of individual thymocyte subsets did not suggest a block at
any specific stage in T cell development. Evaluation of mixed
bone marrow chimeric mice confirmed diminished STING
N153S T cell numbers at all stages of development, including at the DN1 stage, consistent with what was observed in
mixed chimeric mice (Fig. 7 N).These results suggest that the
STING N153S mutation exerts hematopoietic cell-intrinsic
deleterious effects on the early stages of thymocyte development. This result also is consistent with prior in vitro studies demonstrating that a different SAVI-associated mutation
(STING V155M) caused cell-intrinsic effects in human T
cells (Cerboni et al., 2017), although our in vivo findings sug-

gest that T cell cytopenia results mostly from cell-intrinsic
effects on early T cell precursors.
Activation of STAT and mTORC1 signaling in
STING N153S splenocytes
To further investigate the effects of STING N153S on cell
signaling, we used CyTOF to assess phosphorylation status of
TBK1, STAT1, STAT3, STAT5, SHP2, 4E-BP1, S6, and the
presence of Ki67, a marker of cellular proliferation. In STING
N153S splenocytes, we observed a pronounced activation of
the mTORC1 pathway (phospho-S6 and phospho-4E-BP1)
in immune cell subsets known to express STING (monocytes, T cells, NK cells, and cKit+ immature myeloid cells; Liu
et al., 2014; Kobayashi et al., 2015) as well as increased activation of STAT3 and STAT5 in monocytes and NK cells,
respectively (Fig. 8, A and B). These data suggest that the
JEM

STING N153S mutation results in activation of mTORC1,
STAT3, and STAT5 signaling in specific immune cell subsets
that may occur as a result of either cell-intrinsic or -extrinsic
effects of the mutation.
Because SAVI patient PBMCs exhibit a type I IFN gene
expression signature (Liu et al., 2014), we examined whether
STING N153S mice also up-regulate expression of ISGs.
Using RNA-sequencing, and confirmed by quantitative
RT-PCR (qRT-PCR), we detected only an approximately
twofold up-regulation of ISGs in MEFs and splenocytes compared with WT littermate controls (Fig. 9, A and B), suggesting only mild up-regulation of type I IFN signaling. This
ISG signature is much weaker in comparison to Trex1−/−
mice, which exhibit constitutive STING activation and an
interferonopathy with clinically distinct manifestations of
disease (Morita et al., 2004), and in which the majority of
5
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Figure 4. Hypercytokinemia in STING N153S mice. (A–P) Serum was collected from 4–6-mo-old STING N153S and WT littermate control mice, and
cytokine and chemokine levels were measured by Bio-Plex assay (n = 9 mice per group). Data represent the mean from two independent experiments.
*, P < 0.05; **, P < 0.005 by Mann–Whitney.

ISGs within the same panel were markedly elevated (17-fold
compared with WT littermate controls; Fig. 9, A and B). Because Trex1−/− cells accumulate self-DNA that constitutively
activates STI
NG through the cGAS-STI
NG-TBK1-IRF3
pathway (Hasan et al., 2013), our results collectively suggest
that STING N153S does not cause potent activation of type
I IFN signaling in vivo in mice. Next, we decided to correlate
our findings with human SAVI patient samples and found
that only one of two SAVI patient fibroblasts with the STING
N154S mutation exhibited significant up-regulation of ISG
expression (Fig. 9, C and D). Similarly, we did not detect
enhanced cGAMP-mediated activation of STING in patient
cells compared with healthy controls or in STING N153S
MEFs compared with WT littermate control MEFs (Fig. S2,
A–F), although we observed up-regulation of ISGs in 293T
cells that overexpress mouse STING N153S in this study (Fig.
S2 G) and also in our prior study comparing human STING
N154S and mouse STING N153S in parallel (Dobbs et al.,
2015). These findings suggest that the STING mutations may
exhibit differential effects in cell lines and in primary cells,
6

or that overexpression produces a more pronounced effect
on expression of ISGs.
SAVI has been postulated to result from STI
NGmediated activation of IRF3, which potently up-regulates
expression of ISGs, so we initially hypothesized that genetic
deletion of IRF3 would rescue the mice from disease. To test
this hypothesis, we generated Irf3−/− STING N153S mice.
Unexpectedly, we observed a similar degree of perivascular
immune cell infiltration in Irf3−/− STING N153S mice compared with STING N153S control animals (Fig. 9, E and F).
Conversely, Irf3−/− STING N153S MEFs exhibited reduced
IFIT1 and ISG15 expression compared with STING N153S
MEFs (Fig. 9 G), confirming that IRF3 is required for STING
N153S-dependent up-regulation of IFIT1 and ISG15. IRF7
is up-regulated in a positive feedback loop downstream of
IRF3 and IFN-β (Marié et al., 1998; Sato et al., 1998), but we
did not detect any up-regulation of IRF7 in vivo or in vitro
(Fig. 9, A–D).
To determine whether IRF3 is required for STING
N153S-mediated myeloid cell expansion and T cell cytopenia,
Mouse model of STING-associated vasculopathy | Warner et al.
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Figure 5. WT and STING N153S immune cell populations. WT and STING N153S splenocytes were analyzed by CyTOF. (A) viSNE map of WT and
STING N153S splenocytes illustrating color-coded cell populations that clustered based on cell surface marker expression. (B) viSNE map indicating the level
of CD3 marker expression in immune cell populations defined in A. (C) Density plots of immune cell populations defined in A. (D–I) Total number of CD45+
(D), CD19+ (E), CD3+ (F), CD4+ (G), CD8+ (H), and Ly6G+ (I) cells in WT littermate control and STING N153S splenocytes. Horizontal bars represent the mean
of n = 6 samples from two independent experiments. **, P < 0.005 by Mann-Whitney test. (J and K) Heat maps illustrating the calculated arcsinh ratios of
median intensities of CD25, CD11b, and CD44 expression in CD4+ (J, left), CD8+ (J, right), NK1.1+ (K, left), and CD3+CD4−CD8− (CD3+DN; K, right) splenocytes.
*, P < 0.05; **, P < 0.005 by Mann-Whitney test.

we assessed WT, STING N153S, Irf3−/−, and Irf3−/− STING
N153S splenocytes by flow cytometry. We observed similarly increased numbers of Ly6G+ and Ly6C+ myeloid cell
populations in Irf3−/− STI
NG N153S mice and STI
NG
N153S control animals (Fig. 9, H–J; P > 0.7). Additionally,
the percent and absolute number of CD8+ T cells were similarly reduced in splenocytes from Irf3−/− STING N153S and
STING N153S mice (Fig. 9, K and L) compared with their
respective controls.Thus, lung disease, myeloid cell expansion,
and CD8+ T cell cytopenia occur independently of IRF3 signaling in this STING N153S mouse model of SAVI.
DISCUSSION
Our study demonstrates that a SAVI-associated STING mutation causes spontaneous inflammatory lung and skin disease
JEM
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Figure 6. WT and STI
NG N153S mixed bone marrow chimeras.
(A) Diagram depicting the approach for generation of WT littermate and
STING N153S mixed bone marrow chimeras (n = 10). (B) Representative
contour plots of circulating CD4+ (top) and CD8+ (bottom) donor T cells.
(C) Percentage of Thy1.1− WT littermate or STING N153S circulating CD4+
and CD8+ cells from mixed bone marrow chimeras. Data represent the
mean of samples collected from n = 10 mice from two independent experiments. ****, P < 0.0001 by Mann–Whitney.

in mice. However, certain features of the disease in mice were
distinct from clinical features of SAVI in humans. For example,
STING N153S mice did not develop pulmonary fibrosis, and
we did not observe a significant type I IFN gene expression
signature in mice, which has been reported in humans with
SAVI. However, species-specific effects of a disease-causing
mutation are not entirely unexpected. For example, humans
lacking functional TREX1, which leads to type I IFN proNG signaling, develop
duction caused by constitutive STI
spontaneous brain inflammation (Crow et al., 2006), whereas
mice lacking Trex1 develop an interferonopathy with myocarditis (Morita et al., 2004). In contrast to the differential effects of Trex1 mutations in humans and mice, STING N153S
mice and SAVI patients have some interesting cross-species
similarities, including organ-specific inflammation (e.g., skin
and lung disease) as well as T cell cytopenia.
Up-regulation of ISGs occurs in PBMCs of SAVI patients (Liu et al., 2014; Picard et al., 2016), but whether type
I IFN plays a causal role in the human disease remains to be
determined. Importantly, some of the clinical manifestations
of SAVI are distinct from other interferonopathies such as
Aicardi-Goutières syndrome, a disease in which the STING
pathway is chronically activated because of loss of TREX1
function (Crow and Manel, 2015). One view is that SAVI
pathogenesis is mediated by IRF3-induced activation of the
type I IFN response (Liu et al., 2014; Kim et al., 2016; Melki
et al., 2017), as occurs in other interferonopathies (Crow
and Manel, 2015; Kim et al., 2016), but this had not previously been tested experimentally in an animal model with a
human disease-causing STING mutation. We observed only
mild effects on ISG expression in STING N153S MEFs,
and these effects were abolished in the absence of IRF3
(Fig. 9 G), demonstrating that there was indeed some mild
IRF3-dependent up-regulation of certain ISGs in MEFs. Additionally, we observed mild up-regulation of ISGs in patient
NG N154S mutation.
fibroblast cell lines bearing the STI
Our results demonstrate that the STING N153S mutation
causes inflammatory lung and skin disease in mice without
substantive up-regulation of ISGs in primary cells, without
up-regulation of IRF7 in vivo or in vitro, and without IRF3,
a major downstream effector thought to promote disease in
patients with SAVI. Nevertheless, additional studies in STING
N153S mice lacking the type I IFN receptor are still required
to completely exclude any contribution of type I IFN in this
mouse model of SAVI. Given that IRF3 does not play a role
in the disease in mice, it seems plausible that STING mutations in humans also cause disease via other mechanisms and
that up-regulation of type I IFN in patient PBMCs might
be an epiphenomenon. Alternatively, mechanisms of disease
pathogenesis may be entirely distinct in humans with SAVI
and the STING N153S mice, with type I IFN playing a more
important role in the human disease.
In patients with systemic sclerosis and interstitial lung
disease, there is an association between type I IFN and pulmonary fibrosis, suggesting a possible role for type I IFN in

fibrosing lung disease (Eloranta et al., 2010). Based on association, pulmonary fibrosis in SAVI patients also may be influenced by type I IFN (Picard et al., 2016). We found that the
STING N153S knock-in mice universally developed chronic
lung inflammation by age 3–4 mo, but without evidence of
fibrosis even in mice that were examined after death from
respiratory distress. However, mice older than 6 mo were not
assessed. Chronic inflammation may eventually cause fibrosis
in older animals that survive longer. Alternatively, the relative
absence of a type I IFN gene expression signature in STING
N153S mice may be one reason the animals failed to develop
fibrosing lung disease.
STING exerts multiple effects on the pathogenesis of
autoimmune disease. Aside from its capacity to up-regulate
ISGs, the TREX1-cGAS-STING pathway modulates cellular
senescence (Yang et al., 2017), adaptive immunity (Fu et al.,
2015; Cerboni et al., 2017), and production of proinflamma8

tory cytokines (Abe and Barber, 2014). Paradoxically, STING
also limits autoantibody generation and type I IFN production as well as nephritis in lupus-prone mice (Sharma et al.,
2015). Furthermore, STING deficiency unexpectedly led to
hyperresponsiveness of macrophages to TLR7 and TLR9 ligands (Sharma et al., 2015). Thus, in addition to its effects on
type I IFN signaling, the STING N153S mutation is likely to
influence multiple cellular and immunological pathways in a
variety of ways that also could contribute to disease.
A prior study found that STING regulates T cell proliferation in cell culture independently of IRF3 (Cerboni et
al., 2017). Consistent with these previous in vitro findings
that used SAVI patient cells with the V155M mutation, we
demonstrated that the STING N153S mutation affects T cells
in mice in an IRF3-independent manner, and that this was
caused by hematopoietic cell-intrinsic effects. In addition to
altered proliferation of T cells, our mixed bone marrow chiMouse model of STING-associated vasculopathy | Warner et al.
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Figure 7. CyTOF analysis of thymocytes from WT and STING N153S mice. Thymocytes were harvested from 4–6-mo-old WT and STING N153S mice
and analyzed by CyTOF. (A) viSNE map of representative WT and STING N153S thymocyte populations illustrating color-coded cell populations that were
clustered together based on similarity in cell surface marker expression. (B) Contour plots of viSNE maps illustrating the density of cell populations as defined in A. (C–M) The total number of thymocytes was determined. The percentage of thymocytes labeled with each of the respective surface markers was
measured by CyTOF and used to calculate the total numbers of CD45+ cells (C). Percentages of other populations are displayed as follows: CD4−CD8− (double
negative; D), CD4+CD8+ (double positive; E), CD4+ (F), CD8+ (G), CD19+ (H), NK1.1+(I), CD25−CD44+ (DN1; J), CD25+CD44+ (DN2; K), CD25+CD44− (DN3; L), and
CD25−CD44− (DN4; M) cells. (N) Percentage Thy1.1− WT littermate or STING N153S double-negative thymocytes from mixed bone marrow chimeras. Data in
C–M represent the mean of samples from n = 6 mice per genotype from two independent experiments analyzed by Mann-Whitney test. **, P < 0.005. Data
in N represent the mean of samples from n = 3 bone marrow chimeric mice analyzed by unpaired t test. ****, P < 0.0001.

Figure 8. STING N153S mice exhibit altered immune cell signaling. (A and B)
Splenocytes were harvested from 4–6-mo-old
WT and STING N153S mice and analyzed by
CyTOF. (A) Representative SPA
DE plots of
phospho-TBK1 (top) and phospho-S6 (bottom)
in WT and STING N153S splenocytes. Size of
nodes reflects the cell number, and color reflects transformed median intensities of the
phosphoprotein signal. (B) Heat maps depicting calculated arcsinh ratios of median intensities of phosphoprotein signal in WT and STING
N153S splenocytes. Data were pooled from
two independent experiments with n = 6 mice.
*, P < 0.05; **, P < 0.005 by Mann–Whitney test.
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mera studies revealed that STING N153S impacts T cells at
the early stages of thymocyte development. Similar to the
effects of STING N153S on T cells, myeloid cell expansion
in the STING N153S mice also occurred independently of
IRF3. Because the STING N153S mice develop immune
cell abnormalities resembling those observed in SAVI patients, future therapeutic studies will determine whether WT
bone marrow transplantation into STING N153S recipients
may protect animals from disease, which may have implications for clinical practice.
In summary, our STI
NG N153S knock-in mouse
model demonstrates a role for a human disease–causing
mutation in immune cell homeostasis and inflammatory
lung and skin disease in mice. This mouse model will serve
as an important tool to define mechanisms of STI
NGJEM

induced autoinflammatory disease, including type I IFNindependent effects, in the context of a human disease–
causing mutation.
MATERIALS AND METHODS
Design
The goal of our study was to define the disease phenotype of
mice heterozygous for the STING N153S mutation. Power
analysis was conducted for institutional animal care and use
committee–approved in vivo studies to determine the number
of animals needed per experimental group.A minimum of two
independent in vivo experiments were conducted to replicate
findings. No randomization of animals was used for experiments, but WT littermate control animals were used in all studies of STING N153S mice. No outliers were excluded from
9
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Figure 9. STING N153S triggers perivascular pulmonary inflammation, myeloid cell expansion, and T cell cytopenia independently of IRF3. (A)
Expression of ISGs in STING N153S, STING knockout (Sting−/−), and Trex1−/− MEFs as well as STING N153S and Sting−/− spleens. Each data point represents
a unique ISG as fold increase compared with a WT littermate control. Data were assembled using ISG expression values from RNA-sequencing. (B) qRT-PCR
analysis of ISGs in WT, STING N153S, Sting−/− MEFs. mRNA expression is normalized to WT. (C) ISG expression in two healthy control (HC) and SAVI patient
skin fibroblasts. Data represent a selection of ISGs assembled from RNA-sequencing. (D) qRT-PCR analysis of ISGs in skin fibroblasts. Data are from two
independent experiments with two technical replicates per ISG, normalized to HC. (E) Hematoxylin and eosin images of lungs from Irf3−/− and Irf3−/− STING
N153S mice (4–6 mo of age). Pulmonary vessels are indicated (v) with black arrows highlighting perivascular immune cell infiltration. Pulmonary vessels
are indicated (v) with arrows. Bar, 100 µm. (F) Quantitation of perivascular lung lesions in STING N153S (n = 7) and Irf3−/− N153S (n = 4) mice. Results in
F represent the mean ± SEM of data collected and analyzed in two independent experiments. (G) ISG mRNA expression in Irf3−/− and Irf3−/− N153S MEFs
normalized to gene expression in Irf3−/− MEFs. Data represent the mean ± SEM from two independent experiments with n = 3 biological replicates per
genotype. (H–J) Representative dot plots (H) and quantification (I and J) of splenic myeloid cell populations from WT, STING N153S, Irf3−/−, and Irf3−/−
10
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analyses. There was no blinding with regard to data analyses
with the exception of histological analysis, which was carried
out in a blinded fashion.The number of technical and biological replicates for each experiment is listed in the figure legends.
Study approvals
Patient fibroblasts were provided by R. Goldbach-Mansky
(NIAID, NIH, Bethesda, MD), were de-identified, and were
studied under UT Southwestern Medical Center institutional
review board approval for de-identified human samples. Animal protocols were approved by the Institutional Animal Care
and Use Committees at the Washington University School of
Medicine (assurance no. A-3381-01) and UT Southwestern
Medical Center (assurance no. APN2011-0081).

Mice
Mice were housed in pathogen-free mouse facilities at the
Washington University School of Medicine and UT Southwestern Medical Center and given standard diet and water ad
libitum. ICR/CD1 mice were provided by the Hope Transgenic Mouse Core at Washington University in St. Louis.
Sting−/− mice were gifts from G. Barber (University of Miami,
Miami, FL). The congenic backcrossed Irf3−/− mice (Sato et
al., 2000) were gifts of T. Taniguchi (Tokyo, Japan) and provided by colleagues in the United States (I. Rifkin, Boston,
MA; K. Fitzgerald, Worcester, MA).
Generation of mixed bone marrow chimeras
Femurs, tibias, and pelvises were dissected from STI
NG
N153S, WT littermate controls, and Thy1.1 mice. Bone marrow was flushed from bones, and red blood cells were lysed
with ACK lysis buffer. Debris was removed by passing cells
through a 70-µM strainer and counted via hemocytometer.
WT or STING N153S bone marrow was mixed with Thy1.1
bone marrow at a 1:1 ratio, and a total of 10 × 106 cells were
transplanted into CD45.1 hosts via retroorbital i.v. injection.
Hosts received two doses of whole-body irradiation (500 rads,
total 1,000 rads) 5 h apart, 24 h before transplantation. Chimeras were bled 6 wk after transplantation for FACS analysis of
circulating immune cells.Three animals per group were euthanized ∼10 wk after transplantation for analysis of thymocytes.
Antibodies and other reagents
Antibodies used for flow cytometry include the following:
FITC–anti-CD19 (rat IgG2a; 1:200, #115506; BioLegend),
PE–anti-CD45.1 (mouse [A.SW] IgG2a; 1:100, #110707;
BioLegend), PE/Cy7–anti-Thy1.1 (mouse IgG1; 1:100,
#202518; BioLegend), BV421–anti-CD4 (rat IgG2b; 1:150,
#100438; BioLegend), APC–anti-CD45.2 (mouse [SJL]
IgG2a; 1:100, #109813; BioLegend), V500–anti-CD3e (Syrian hamster IgG2; 1:50, #560771; BD Biosciences), FITC–
anti-CD25 (rat IgG2b; 1:100, #101907; BioLegend), PerCP/
Cy5.5–anti-CD19 (rat IgG2a; 1:100, #152405, BioLegend),
PerCP/Cy5.5–anti-NK1.1 (mouse IgG2a; 1:100, #108727;
BioLegend), PerCP/Cy5.5–anti-CD8b (rat IgG2b; 1:100,
#126609; BioLegend), BV605–anti-CD44 (rat IgG2b; 1:100,
#103047; BioLegend), FITC–anti-CD8a (rat IgG2a; 1:100,

STING N153S mice. Data represent the mean of two independent experiments with n = 4 or 5 mice per genotype. (K and L) Percentage (K) and total number
(L) of CD8+ splenocytes from WT, STING N153S, Irf3−/−, and Irf3−/− STING N153S mice. Data were pooled from two independent experiments with n = 4 or
5 mice per genotype. ns, not significant; *, P < 0.05; **, P < 0.005 by Mann–Whitney test.
JEM
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Generation of STING N153S knock-in mice
A single guide RNA (sgRNA; 5′-GTTAAATGTTGCCCA
 CTG
 G-3′) was designed based on specificity and proxCGGG
imity to the targeted Tmem173 (STING) mutation site. Efficiency of genomic DNA cutting was tested in an in vitro cell
line assay as previously described (Parikh et al., 2015).T7 templates for gRNA and WT Cas9 (px330) were prepared by PCR
amplification and purified by Qiaquick PCR purification spin
columns (Qiagen). RNA synthesis was then performed according to the manufacturer’s protocol using the Megashortscript
SAGE mMAC
kit (Thermo Fisher Scientific) and mMES
HINE T7 Ultra kit (Thermo Fisher Scientific), for sgRNA and
Cas9 mRNA, respectively. RNA was purified using MEGAclear RNA purification kit (Life Technologies; sgRNA) or by
lithium chloride precipitation (Cas9 mRNA) and diluted in
nuclease-free injection buffer. A single-stranded oligonucleotide donor (ssODN) encoding the amino acid substitution
(N153S) with 99-nucleotide homology arms was synthesized
by IDT (Ultramer oligo): 5′-gctttggacatcccccttgaaagtccctcaggcccttctgctgtcttcagAGCTTGACTCCAGC-GGAAGTCTC
TGCAGTC TGT GAAGAA AAG AAG TTAtcTGTT GC
CCAC GGG CTG GCC TGG TCATAC TACATT GGG TA
CTTGCGGTTGATCTTACCAGgtagggcacctctggatgttgatgtgtggacaacaaaacac-3′ (exonic sequence in uppercase, flanking intronic sequence in lowercase, and mutant nucleotides in
underlined lowercase). Female C57BL/6N mice, 4 wk of age,
were superovulated and mated with C57BL/6N males. Single-cell embryos (embryonic day 0.5 [E0.5]) were isolated and
injected with a combination of either 50 ng/μl Cas9, 25 ng/
μl gRNA, and 100 ng/μl ssODN or a combination of 25 ng/
μl Cas9, 13 ng/μl gRNA, and 100 ng/μl ssODN in DNase/
RNase-free microinjection buffer (1 mM Tris and 0.25 mM
EDTA, pH 7.4). Over the course of 6 d of microinjection,
∼80–100 modified embryos per day were transferred into E0.5
pseudo-pregnant ICR/CD1 female recipient mice. Two in-

dependent founder mice were backcrossed to WT animals for
five generations, and WT littermate controls were used for all
experiments. Experiments were performed on mice between
12 and 24 wk of age, including equal numbers of mice of both
sexes, with matched littermate control animals. Sample sizes
were chosen according to our previously published studies.
Mice were randomly allocated for all experiments.

#100705; BioLegend), BV510–anti-CD11b (rat IgG2b; 1:100,
#101245; BioLegend), BV421–anti-Ly6C (RçAT IgM; 1:100,
#562727; BD Biosciences), and PerCP/Cy5.5–anti-Ly6G
(rat IgG2a; 1:100, #127615; BioLegend). For mass cytometry experiments, metal-tagged antibodies were obtained from
Fluidigm or conjugated using the Maxpar X8 Antibody Labeling kit according to the manufacturer’s instructions (Fluidigm). Clone and tag information can be found in Table S1.

Primary cell isolation and culture
Primary WT littermate, heterozygous STING N153S, Irf3−/−,
Irf3−/− heterozygous STI
NG N153S, and Sting−/− MEFs
(Ishikawa and Barber, 2008; gift from G. Barber) were generated from embryos on E13.5. MEFs were transfected with
SV2 plasmid, encoding the large T antigen of SV40 polyomavirus. Cells were passaged ∼10 times and used for subsequent experiments. In some experiments, primary MEFs
were used to confirm phenotypes observed in transformed
MEFs. Cell lines were genotyped to confirm their identity.
Human fibroblasts were generated from SAVI patients and
healthy controls (Liu et al., 2014; gift to the Yan laboratory
from R. Goldbach-Mansky). All cells were cultured at 37°C
with 5% CO2 in DMEM supplemented with 10% FBS and
2 mM l-glutamine, 1× nonessential amino acid solution,
1 mM sodium pyruvate, 10 mM Hepes, 100 U/ml penicillin,
and 100 mg/ml streptomycin.
Cytokine assay
Mouse serum was collected by terminal exsanguination of
anesthetized mice and stored at −20°C before measurement of cytokine and chemokine levels on the Luminex
platform using the Bio-Plex Pro Mouse Cytokine Group I
Panel 23-Plex Assay kit (Bio-Rad). The BioPlex Pro Assay
was performed according to the manufacturer's protocol. Cytokines and chemokines tested include IL-1α, IL-1β, IL-2,
IL-3 IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL13, IL-17, eotaxin, G-CSF, GM-CSF, IFN-γ, Iα, MIP-1β,
RANTES (CCL5), and TNF.
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Stimulation of cell lines with cGAS-STING ligands
Transfections of 2′3′-cGAMP (Invivogen), htDNA (SigmaAldrich), and poly I:C (Sigma-Aldrich) were performed
using Lipofectamine 2000 (Thermo Fisher Scientific) as previously described (Dobbs et al., 2015). After 6 h of treatment,
RNA was isolated using Trizol (Sigma-Aldrich), and ISGs
and IFN-β were measured via qRT-PCR.
qRT-PCR
Total RNA was isolated by RNeasy kit (Qiagen) per manufacturer’s protocol. RNA was quantified and quality confirmed using a NanoDrop ND-1000 spectrophotometer.
cDNA was synthesized with iScript cDNA synthesis kit (BioRad). iTaq Universal SYBR Green Supermix (Bio-Rad) and
an ABI-7500 Fast Real-Time PCR system (Applied Biosystems) were used for qRT-PCR. Alternatively, in some experiments,TaqMan RNA-to-Ct 1-Step kit (Applied Biosystems)
was used to measure mRNA expression. Ct values for all target genes were normalized to Ct values of the housekeeping
gene GAPDH. Data are reported as ΔCt (Cttarget – CtGAPDH).
CyTOF
Spleen and thymus tissues were isolated from WT and STING
N153S mice and mashed through 70-µm Nylon cell strainers,
washed twice with culture media, and treated with RBC lysis
buffer. Cells were then washed with CyFACS (0.1% BSA,
2 mM EDTA, and 0.02% NaN2 in PBS; Rockland) followed
by CyPBS. For viability staining, cells were incubated with
2.5 µM cisplatin for 1 min at room temperature, washed twice
in CyFACS, and fixed in 1.5% PFA (final concentration) for 10
min at room temperature. After two washes, 3 × 106 cells per
sample were incubated for 10 min with Fc block, after which
a cocktail of 17 surface markers (Table S1) was added and incubated with the cells for 1 h on ice. Cells were washed in CyFACS and permeabilized with ice-cold methanol overnight at
−20°C. The next day, cells were washed twice with CyFACS
and incubated with a cocktail of 11 intracellular antibodies on
ice for 1 h (Table S1). Cells were washed, suspended in CyPBS
containing iridium-intercalator (DNA stain; Fluidigm) and
2% PFA, and stored at 4°C overnight. Before acquisition on
a CyTOF2 mass cytometer (Fluidigm), cells were counted,
washed with ddH2O water, and suspended in EQ Four Element calibration beads (Fluidigm) per the manufacturer’s
instructions. Normalization was performed using Normalizer
v0.3 Matlab Complier Runtime (GitHub; Nolan laboratory),
and Cytobank (cytobank.org) was used for data analysis and
generation of SPA
DE trees, viSNE maps, and heat maps.
Splenocyte populations were clustered in each viSNE map by
CD45, CD4, CD8α, CD11b, Ly6G, CD3ε, CD19, NK1.1, and
MHCII, whereas thymocyte populations were clustered by
Mouse model of STING-associated vasculopathy | Warner et al.
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Genotyping
Toe clips were digested with proteinase K, and DNA was
isolated with the Qiagen kit per manufacturer’s protocol.Two
separate PCR reactions were performed for genotyping: a
WT allele PCR and a STING N153S mutant allele PCR.
WT primer (5′-GTCTGTGAAGAAAAGAAGTTAAA-3′)
or STING N153S forward primer (5′-GTCTGTGAAGAA
AAGAAGTTAAC-3′) and reverse primer (5′-GTGATT
TTATGTACCCTGGG-3′) recognizing sequences in exon
5 of Tmem173 (STING) were added to PCR SuperMix (Invitrogen) at a final concentration of 0.4 µM. PCR was performed with an initial denaturation (94°C, 2 min), followed
by 34 cycles of denaturation (94°C, 30 s), annealing (47°C,
45 s), and extension (72°C, 1 min). Mice positive for the
STING N153S mutation were identified by the appearance
of a 258-bp band by agarose gel electrophoresis.

Autoantigen arrays
Autoantigen arrays were performed on serum samples by the
University of Texas Southwestern Medical Center Microarray
Core as previously described (Li et al., 2005).

CD45,TCRβ, CD4, CD8α, CD11b, Ly6G,TER119,TCRγδ,
B220, CD3ε, CD19, NK1.1, CD117, and MHCII. Natural
separations in the viSNE map combined with marker-dependent color-coding of dot plots were used to manually draw
gates and define populations. Cell populations represented in
SPADE trees and heat maps were also manually defined according to cell surface marker expression as explained in Table
S2. For analysis of heat map data and comparison of signal
intensity, log10 scales were compressed according to the arcsinh
transformation as previously described (Bendall et al., 2011)
and in accordance with the standard analytical procedure for
mass cytometry data on cytobank.org.

Flow cytometry
Immunophenotyping of spleens was performed on a
FACSCanto flow cytometer (BD Biosciences) and analyzed
using FlowJo software.
Statistics
Unless otherwise specified, all data were analyzed using GraphPad Prism software by Mann–Whitney or t test as specified in
the figure legends. Flow cytometry data were analyzed using
FlowJo, and CyTOF results were analyzed using cytobank.org.
Online supplemental material
Supplemental material associated with this study includes
FACS characterization of infiltrating immune cells in the
lungs of STING N153S mice (Fig. S1), as well as a comparison of type I IFN and ISG induction in patient and
mouse fibroblasts and also in transfected 293T cells (Fig.
S2). Supplemental tables include CyTOF panels (Table
S1) and definitions of immune cell populations from
CyTOF analysis (Table S2).
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Figure S1. Pulmonary immune cell analysis of WT and STING N153S mice. (A–F) Flow cytometry analysis of immune cells isolated from the lungs of
WT and STING N153S mice. Total numbers were determined for the following immune cell subsets: CD3+ (A), CD4+ (B), CD8+ (C), CD19+ (D), CD11b+ (E), and
CD49b+ populations (F). Data represent the mean ± SEM of n = 3 mice per group. *, P < 0.05, ***, P < 0.0005 by unpaired t test.

JEM

S15

Figure S2. IFN-β and ISG expression in primary STING N154S patient skin fibroblasts, STING N153S MEFs, and transfected 293T cells. (A–F)
Cells were stimulated with increasing amounts of 2′3′-cGAMP (2, 4, and 8 µg), herring testes DNA (htDNA; 0.1, 0.5, and 1 µg) and polyinosinic–polycytidylic
acid (poly I:C; 0.1, 0.5, and 1 µg) for 6 h. There was no significant difference cGAMP-transfected WT and STING N153S MEFs or between healthy control and
STING N154S skin fibroblasts. Data were analyzed by ANOVA. (G) ISG expression in 293T cells 24 h after overexpression of WT mouse or mutant STING N153S
as previously described (Dobbs et al., 2015). ***, P < 0005; ****, P < 0.0001 by t test. Stimulations were performed in biological triplicates, and qRT-PCR was
performed in technical triplicates. Data represent the mean ± SEM.

S16

Mouse model of STING-associated vasculopathy | Warner et al.

Table S1. Antibodies used in CyTOF
Tag

Target

Clone

Manufacturer

Catalog #

089Y
141Pr
142Nd
143Nd
145Nd
146Nd
147Sm
148Nd
149Sm
150Nd
151Eu
153Eu
154Sm
155Gd
158Gd
159Tb
160Gd
161Dy
164Dy
165Ho
166Er
168Er
170Er
171Yb
172Yb
173Yb
174Yb
176Yb

CD45
pSHP2
Caspase 3 (Cleaved)
TCRβ
CD4
CD8α
pSTAT5
CD11B (Mac-1)
p4E-BP1
CD25
Ly-6G
pSTAT1
TER119
pTBK1/NAK
pSTAT3
TCRγδ
CD45R (B220)
pBAD
IκBα
CD3ε
CD19
Ki67
NK1.1
CD44
pS6
CD117 (c-kit)
MHCII
pCREB

30-F11
D66F10
D3E9
H57-597
RM4-5
53-6.7
47
M1/70
236B4
3C7
1A8
58D6
TER-119
D52C2
4/P-Stat3
GL3
RA3-6B2
40A9
L35A5
145-2C11
6D5
B56
PK136
IM7
N7-548
2B8
M5/114.15.2
87G3

Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
CST
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm

3089005B
3141002A
3142004A
3143010B
3145002B
3146003B
3147012A
3148003B
3149005A
3150002B
3151010B
3153003A
3154005B
5483BF
3158005A
3159012B
3160012B
3161006A
3164004A
3165020B
3166015B
3168007B
3170002B
3171003B
3172008A
3173004B
3174003B
3176005A

Table S2. Definition of populations used in CyTOF analysis
Cell populations
Fig. 5
CD4 (CD4 T cells)
CD8 (CD8 T cells)
NK (NK cells)
CD19 (B cells)
Ly6G+ (CD11bhi Ly6Ghi)
Monocytes
Immature myeloid
CD3 double-negative (DN)
Fig. 6
CD4+ CD8−
CD8+ CD4−
CD4+ CD8+
CD4− CD8−
CD19+ B220+
NK1.1+
DN1
DN2
DN3
DN4
Fig. 7
B cells
T cells
Monocytes
NK cells
Immature myeloid

JEM

Marker expression
CD45+ TER119− CD3+ CD4+ TCRβ+
CD45+ TER119− CD3+ CD8+ TCRβ+
CD45+ TER119− NK1.1+ CD3−
CD45+ TER119− CD19+ B220+ MHCII+/int/lo
CD45+/lo TER119− CD11bhi Ly6Ghi
CD45+ TER119− CD11b+ Ly6G− MHCII−
CD45lo TER119− CD117+/lo CD11b+ Ly6Gint/lo/CD45+ TER119− CD3+ CD4− CD8−
CD45+ TER119− B220− CD19− NK1.1− CD4+ CD8−
CD45+ TER119− B220− CD19− NK1.1− CD8+ CD4−
CD45+ TER119− B220− CD19− NK1.1− CD4+ CD8+
CD45+ TER119− B220− CD19− NK1.1− CD4− CD8−
CD45+ TER119− B220+ CD19+
CD45+ TER119− B220− CD19− NK1.1+
CD45+ TER119− B220− CD19− NK1.1− CD4+ CD8+ CD44+ CD25−
CD45+ TER119− B220− CD19− NK1.1− CD4+ CD8+ CD44+ CD25+
CD45+ TER119− B220− CD19− NK1.1− CD4+ CD8+ CD25+ CD44 lo/CD45+ TER119− B220− CD19− NK1.1− CD4+ CD8+ CD44lo/− CD25−
CD45+ TER119− CD3− CD19+
CD45+ TER119− CD19− CD3+
CD45+ TER119− CD3− CD19− CD11b+ Ly6G− MHCII−
CD45+ TER119− CD19− CD3− NK1.1+
CD45+ TER119− CD3− CD19− CD11b+ MHCII−
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